ProStrakan is a rapidly growing speciality pharmaceutical company engaged in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. There are certain key elements of ProStrakan’s business model for example to selectively invest in the company’s development portfolio. The company’s main marketed products are Adcal D3™, Rectogesic™, Tostran™, droperidol, Isotard XL™ and Tebetane™.